Protalix BioTherapeutics Announces New Clinical Data on Taliglucerase Alfa to be Presented at the WORLD Lysosomal Disease

Protalix BioTherapeutics Announces New Clinical Data on Taliglucerase Alfa to
be Presented at the WORLD Lysosomal Disease Network Symposium

CARMIEL, Israel, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,
Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that new clinical data on
taliglucerase alfa will be presented at the 9th Annual Meeting of the
Lysosomal Disease Network: WORLD Symposium 2013 being held February 13-15 in
Orlando, Florida.

Gregory Pastores, M.D., Associate Professor of Neurology and Pediatrics and
Director of the Neurogenetics Laboratory at The New York University School of
Medicine and study investigator will deliver an oral presentation titled:
"Plant Cell–Expressed Recombinant Glucocerebrosidase: Taliglucerase Alfa as
Therapy for Gaucher Disease in Adults Patients Previously Treated with
Imiglucerase: 24-Month Results," on Friday, February 15, 2013 at 11:00 AM
ET.These results will also be presented during the poster sessions, which
will take place on Wednesday, February 13 from 4:30-6:30 PM ET and on
Thursday, February 14 from 4:30-6:00 PM ET.

Additionally, Professor Ari Zimran, M.D., Director of the Gaucher Clinic,
Shaare Zedek Medical Center, Jerusalem, Israel, and study investigator will
present two posters on taliglucerase alfa during the poster sessions. The
titles are as follows:

  o"Long-Term Safety and Efficacy Data of Taliglucerase Alfa, a Plant
    Cell–Expressed Recombinant Glucocerebrosidase, in the Treatment of Naïve
    Gaucher Disease Patients: 36-Month Results."
  o"A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two
    Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher
    Disease."

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins expressed through its
proprietary plant cell based expression system, ProCellEx®. Protalix's unique
expression system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner. Protalix's first
approved product manufactured by ProCellEx, ELELYSO™ (taliglucerase alfa), an
enzyme replacement therapy for the treatment of Gaucher disease, was approved
for marketing by the U.S. Food and Drug Administration in May 2012, and by
Israel's Ministry of Health in September 2012. Additional marketing
applications for taliglucerase alfa have been filed in other
countries.Protalix is partnered with Pfizer Inc. for worldwide development
and commercialization, excluding Israel, where Protalix retains full
rights.Protalix's development pipeline also includes the following product
candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A
protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant
human acetylcholinesterase in development for several therapeutic and
prophylactic indications, a biodefense program and an organophosphate-based
pesticide treatment program; an orally-delivered glucocerebrosidase enzyme
that is naturally encased in carrot cells, also for the treatment of Gaucher
disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel®) for
the treatment of certain immune diseases such as rheumatoid arthritis,
juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and
plaque psoriasis; and others.

CONTACT: Investor Contact

         Marcy Nanus
         The Trout Group, LLC
         646-378-2927
         mnanus@troutgroup.com

         Media Contact

         Kari Watson
         MacDougall Biomedical Communications
         781-235-3060
         kwatson@macbiocom.com